Private Trust Co. NA lowered its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,997 shares of the biopharmaceutical company’s stock after selling 1,991 shares during the period. Bristol-Myers Squibb comprises about 0.8% of Private Trust Co. NA’s investment portfolio, making the stock its 27th biggest holding. Private Trust Co. NA’s holdings in Bristol-Myers Squibb were worth $3,799,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Tradewinds Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 500 shares during the last quarter. Atlantic Trust LLC bought a new position in Bristol-Myers Squibb in the second quarter worth about $111,000. Massey Quick Simon & CO. LLC lifted its holdings in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. lifted its holdings in Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the last quarter. Finally, Horan Capital Advisors LLC. bought a new position in Bristol-Myers Squibb in the third quarter worth about $122,000. 69.56% of the stock is currently owned by hedge funds and other institutional investors.
Bristol-Myers Squibb Co (BMY) opened at $65.35 on Thursday. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The company has a market cap of $106,960.00, a P/E ratio of 110.76, a P/E/G ratio of 1.96 and a beta of 1.08.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date was Thursday, January 4th. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 271.19%.
A number of equities research analysts have recently weighed in on BMY shares. Zacks Investment Research cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price target on the stock. in a report on Thursday, December 28th. SunTrust Banks raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a report on Thursday, October 26th. Finally, Leerink Swann lifted their price target on Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $65.58.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 4,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were purchased at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the transaction, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The disclosure for this sale can be found here. 0.23% of the stock is owned by company insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.